| Field | Specification |
|---|---|
| Target | |
| Alternative names | Probable ATP-dependent RNA helicase DDX58;3.6.4.13;DEAD box protein 58;RIG-I-like receptor 1;RLR-1;Retinoic acid-inducible gene 1 protein;RIG-1;Retinoic acid-inducible gene I protein;RIG-I;DDX58; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human DDX58 recombinant protein (Position: H871-K925). Human DDX58 shares 83.3% amino acid (aa) sequence identity with mouse DDX58. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets antiviral innate immune response receptor RIG-I (gene RIGI) in human, mouse and rat samples and is validated for flow cytometry, ICC/IF and Western blot. The predicted molecular weight is 106.6 kDa, and the supplier reports an observed band at about 107 kDa.
RIG-I (RIGI, previously DDX58) is a cytosolic RNA helicase that detects viral RNA, particularly short double-stranded RNA with a 5′-triphosphate end. On binding, it oligomerizes and engages the adaptor MAVS on mitochondria through its CARD domains, triggering IRF3 and NF-κB activation and production of type I interferons. It is a key sensor in antiviral innate immunity research.
| Target | Antiviral innate immune response receptor RIG-I (gene RIGI; UniProt O95786, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 106.6 kDa |
| Observed MW | 107 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| Immunocytochemistry / Immunofluorescence | 2 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human HepG2 cells, rat C6 cells, human HeLa cells, mouse RAW264.7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (ICC/IF): U2OS cells.
Samples with confirmed staining (ICC/IF): human intestine cancer tissue.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Recombinant human DDX58 fragment (His871–Lys925), expressed in E. coli. Sequence identity with the mouse ortholog: 83.3%.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places antiviral innate immune response receptor RIG-I in the cytoplasm, cell projection and cell junction. Tissue expression noted by UniProt (human): Present in vascular smooth cells (at protein level). The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
